New Delhi : Panacea Biotec, India’s 3rd largest biotechnology company is planning to introduce during Indian Cancer Congress 2011 at Bhubaneswar on 12th Feb 2011; their indigenously developed Albumin bound Paclitaxel particles formulation – PacliALL. PacliALL offers the advantage of improved safety over conventional formulations of Paclitaxel and is meant to be used as a chemotherapeutic agent for the treatment of Breast Cancer. PacliALL would be made available at a price point which is approximately 50% lower than competitive products in the domestic and global markets.

PacliALL has been developed by Panacea Biotec’s state of the art Global Research and Development (GRAND) Centre, Navi Mumbai.

Commenting on the same, Dr. Rajesh Jain, Jt. Managing Director, Panacea Biotec Limited said “The Objective of Panacea Biotec is to take Ideas from Grey Cells to the Market in a Proactive Manner and establishing brand India globally in sync with its adage “Think Medicine Think India”. Pacliall uses one of world’s most advanced particle size optimization technology to reduce serious adverse effects like severe anaphylaxis and sensory neuropathy associated with conventional Paclitaxel formulations in addition to offering several patient convenience aspects like shorter infusion time and elimination of need of premedication. We are in line with our vision to become the Greatest, Largest and Most Admired Biotechnology Company and we are proud to offer this technology to the global population.

Panacea Biotec will remain committed to its mission providing the latest and most affordable preventive and therapeutic care to people across the globe. The launch of PacliALL reflects the hardwork of Panacea Biotec’s scientists, who worked tenaciously for the development of this drug – Added Dr. Rajesh Jain